利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.032 秒)

    AUTOMATED SYSTEM FOR MEASUREMENT OF ZONE 1 IN ASSESSMENT OF SEVERITY OF RETINOPATHY OF PREMATURITY
    1.
    发明申请
    AUTOMATED SYSTEM FOR MEASUREMENT OF ZONE 1 IN ASSESSMENT OF SEVERITY OF RETINOPATHY OF PREMATURITY 审中-公开
    用于测量区域1的自动化系统评估临床前期严重程度

    公开(公告)号：US20160213242A1

    公开(公告)日：2016-07-28

    申请号：US14968622

    申请日：2015-12-14

    申请人： Michael T. Trese ,  Antonio Capone, JR. ,  Kimberly Drenser ,  Carl Park

    发明人： Michael T. Trese ,  Antonio Capone, JR. ,  Kimberly Drenser ,  Carl Park

    IPC分类号： A61B3/00 ,  A61B5/00 ,  A61B3/12

    CPC分类号： A61B3/0025 ,  A61B3/0033 ,  A61B3/1241 ,  A61B5/0022

    摘要： An automated method for diagnosing and evaluating severity of retinopathy of prematurity in a retina of a patient is provided that is superior to conventional techniques. A graphical user interface (GUI) is provided for receiving biographical information for the patient creating a patient record in a database via the GUI. A photograph of the retina of the patient is collected and placed in the patient record via the GUI. The photograph is then analyzed to determine vascular distributions within the retina. A zone 1 boundary is assigned to the retina based on a set of threshold levels with respect to the determined vascular distributions. A system for performing the automated method is also provided.

    摘要翻译： 提供了一种诊断和评估患者视网膜视网膜病变严重程度的自动化方法，其优于常规技术。 提供图形用户界面（GUI），用于接收通过GUI在数据库中创建患者记录的患者的传记信息。 收集患者视网膜的照片，并通过GUI放置在患者记录中。 然后分析照片以确定视网膜内的血管分布。 基于关于所确定的血管分布的一组阈值水平将区域1边界分配给视网膜。 还提供了一种用于执行自动化方法的系统。

    Modification of vitreal matrix metalloproteinase activity
    7.
    发明授权
    Modification of vitreal matrix metalloproteinase activity 失效
    玻璃体基质金属蛋白酶活性的修饰

    公开(公告)号：US06787135B2

    公开(公告)日：2004-09-07

    申请号：US10096568

    申请日：2002-03-13

    申请人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin Dailey

    发明人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin Dailey

    IPC分类号： A61K3848

    CPC分类号： A61K38/484

    摘要： Methods of modifying total MMP activity levels in the vitreous of an eye are provided. In a preferred embodiment, the method results in reduced MMP activity and comprises introducing plasmin into the vitreous of the eye. Enzyme assisted vitrectomy procedures are also provided, and comprise introducing plasmin into the vitreous in an amount sufficient to induce posterior detachment of the vitreous, mechanically detaching the vitreous from the eye, introducing a replacement fluid into the eye, and introducing plasmin into the eye in an amount sufficient to decrease the total MMP activity in vitreous. Considering the purported roles of MMPs in a variety of vitreal pathologies, the present invention provides methods of inhibiting the progression of various disease conditions, including prolifertaive diabetic retinopathy.

    摘要翻译： 提供了改善眼睛玻璃体总MMP活性水平的方法。 在优选的实施方案中，该方法导致MMP活性降低，并且包括将纤溶酶导入眼睛的玻璃体。 还提供了酶辅助的玻璃体切除术，并且包括将纤维蛋白溶胶引入玻璃体中，其量足以引起玻璃体的后脱离，机械地将玻璃体从眼睛中分离出来，将更换的流体引入眼中，并将纤溶酶引入眼中 足以降低玻璃体中总MMP活性的量。 考虑到MMP在各种玻璃体病变中的作用，本发明提供了抑制各种疾病状况（包括增生性糖尿病性视网膜病变）进展的方法。

    Method for vitreous liquefaction
    8.
    发明授权
    Method for vitreous liquefaction 有权
    玻璃体液化方法

    公开(公告)号：US07776026B2

    公开(公告)日：2010-08-17

    申请号：US10068314

    申请日：2002-02-06

    申请人： Michael T. Trese ,  George A. Williams ,  Michael K. Hartzer

    发明人： Michael T. Trese ,  George A. Williams ,  Michael K. Hartzer

    IPC分类号： A61F9/00 ,  A61M31/00

    CPC分类号： A61K38/484

    摘要： A process is disclosed for liquefying the vitreous humor of an eye. The process includes the steps of delivering plasmin into the vitreous of the eye and incubating the vitreous and plasmin together for a period of time. Plasmin may be introduced through injection or a sustained release device. Plasmin may be used to treat a pathological condition of the eye such as diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

    摘要翻译： 公开了一种用于液化眼睛的玻璃体液的方法。 该方法包括以下步骤：将纤溶酶递送到眼玻璃体中并将玻璃体和纤溶酶一起孵育一段时间。 可以通过注射或持续释放装置引入纤溶酶。 纤溶酶可用于治疗眼睛的病理状况，例如糖尿病性视网膜病变，黄斑裂孔，黄斑褶皱，眼内感染，异物眼内物质和视网膜脱离。

    Method for purification of a blood component
    9.
    发明授权
    Method for purification of a blood component 有权
    纯血液成分的方法

    公开(公告)号：US06207066B1

    公开(公告)日：2001-03-27

    申请号：US09178970

    申请日：1998-10-26

    申请人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin A. Dailey

    发明人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin A. Dailey

    IPC分类号： B01D1508

    CPC分类号： C12N9/6435 ,  A61K38/00 ,  B01D15/34 ,  B01D15/361 ,  B01D15/3804 ,  B01J20/3204 ,  B01J20/3219 ,  B01J20/3274 ,  C12Y304/21007 ,  G01N30/6091 ,  Y10T436/25375 ,  Y10T436/255

    摘要： A method for rapid purification of a blood component from blood is described in which the blood plasma is first separated from the cellular blood elements by any conventional means, such as centrifugation. An affinity cartridge is then activated with a molecule, such as an amino acid, which binds with a blood component such as plasminogen. The separated blood plasma is then passed through the affinity cartridge such that the blood component is retained by the affinity cartridge. Thereafter, the blood component is eluted from the affinity cartridge by passing a buffer solution containing a releasing agent through the affinity cartridge. This releasing agent disengages the blood component from the affinity cartridge. The releasing agent is then separated from the eluted solution by passing the eluted solution through a device, such as an ion exchange or size exclusion device. The separated blood component, e.g. plasminogen, is then converted to plasmin by adding a known amount of an enzyme to the solution from which the releasing agent has been removed.

    摘要翻译： 描述了从血液中快速纯化血液成分的方法，其中血浆首先通过任何常规方法如离心分离于细胞血液元件。 然后用与诸如纤溶酶原的血液成分结合的分子（例如氨基酸）活化亲和柱。 然后将分离的血浆通过亲和柱，使得血液成分被亲和柱保持。 此后，通过使含有脱模剂的缓冲溶液通过亲和柱，从亲和柱洗脱血液成分。 该释放剂使血液成分从亲和药筒脱离。 然后通过使洗脱的溶液通过诸如离子交换或尺寸排阻装置的装置将脱模剂与洗脱的溶液分离。 分离的血液成分，例如 然后通过向去除了脱模剂的溶液中加入已知量的酶将其转化为纤溶酶。

    Kit for purification of plasmin
    10.
    发明授权
    Kit for purification of plasmin 有权
    用于纯化纤溶酶的试剂盒

    公开(公告)号：US06183692B2

    公开(公告)日：2001-02-06

    申请号：US09505272

    申请日：2000-02-16

    申请人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin A. Dailey

    发明人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin A. Dailey

    IPC分类号： A61K3514

    CPC分类号： C12N9/6435 ,  A61K38/00 ,  B01D15/34 ,  B01D15/361 ,  B01D15/3804 ,  B01J20/3204 ,  B01J20/3219 ,  B01J20/3274 ,  C12Y304/21007 ,  G01N30/6091 ,  Y10T436/25375 ,  Y10T436/255

    摘要： A method for rapid purification of a blood component from blood is described in which the blood plasma is first separated from the cellular blood elements by any conventional means, such as centrifugation. An affinity cartridge is then activated with a molecule, such as an amino acid, which binds with a blood component such as plasminogen. The separated blood plasma is then passed through the affinity cartridge such that the blood component is retained by the affinity cartridge. Thereafter, the blood component is eluted from the affinity cartridge by passing a buffer solution containing a releasing agent through the affinity cartridge. This releasing agent disengages the blood component from the affinity cartridge. The releasing agent is then separated from the eluted solution by passing the eluted solution through a device, such as an ion exchange or size exclusion device. The separated blood component, e.g. plasminogen, is then converted to plasmin by adding a known amount of an enzyme to the solution from which the releasing agent has been removed.

    摘要翻译： 描述了从血液中快速纯化血液成分的方法，其中血浆首先通过任何常规方法如离心分离于细胞血液元件。 然后用与诸如纤溶酶原的血液成分结合的分子（例如氨基酸）活化亲和柱。 然后将分离的血浆通过亲和柱，使得血液成分被亲和柱保持。 此后，通过使含有脱模剂的缓冲溶液通过亲和柱，从亲和柱洗脱血液成分。 该释放剂使血液成分从亲和药筒脱离。 然后通过使洗脱的溶液通过诸如离子交换或尺寸排阻装置的装置将脱模剂与洗脱的溶液分离。 分离的血液成分，例如 然后通过向去除了脱模剂的溶液中加入已知量的酶将其转化为纤溶酶。